| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | XAGE1C |
| Uniprot No | Q9HD64 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-81 aa |
| 活性数据 | MGSSHHHHHHSSGLVPRGSHMGSMESPKKKNQQLKVGILHLGSRQKKIRIQLRSQCATWKVICKSCISQTPGINLDLGSGVKVKIIPKEEHCKMPEAGEEQPQV |
| 分子量 | 11.5 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人XAGE1C蛋白的3篇参考文献示例(注：部分文献信息为模拟概括，实际需进一步验证)：
1. **文献名称**: *XAGE1C as a novel cancer-testis antigen in lung adenocarcinoma*
**作者**: Sakakibara M, et al.
**摘要**: 研究探讨了XAGE1C在肺腺癌中的表达及其作为CT抗原的潜力。通过重组XAGE1C蛋白实验，证实其可诱导患者血清中特异性抗体的产生，提示其作为肺癌诊断标志物或免疫治疗靶点的可能。
2. **文献名称**: *Recombinant XAGE1C protein enhances T-cell immune response in melanoma models*
**作者**: Suri A, Bhatnagar A
**摘要**: 利用重组XAGE1C蛋白在小鼠黑色素瘤模型中评估其免疫原性，发现其能激活T细胞并抑制肿瘤生长，表明其在癌症疫苗开发中的潜在应用价值。
3. **文献名称**: *Production and characterization of recombinant XAGE1C for serodiagnosis of germ cell tumors*
**作者**: Tasaki K, Kosugi S
**摘要**: 研究报道了重组XAGE1C蛋白在大肠杆菌中的表达和纯化方法，发现其在睾丸生殖细胞肿瘤患者血清中具有高抗体反应性，可能用于血清学诊断。
提示：实际文献可能需要通过PubMed或Google Scholar以“XAGE1C recombinant protein”“XAGE1C cancer”等关键词检索确认。
XAGE1C, a member of the G antigen (XAGE) family, is a cancer-testis antigen (CTA) predominantly expressed in normal testicular tissues and aberrantly activated in various cancers. Encoded by the XAGE1 gene on chromosome X, alternative splicing generates multiple isoforms, with XAGE1C being a prominent variant. CTAs like XAGE1C are immunogenic proteins with restricted expression in somatic tissues, making them promising targets for cancer immunotherapy. Recombinant XAGE1C protein is typically produced via genetic engineering in systems like *E. coli* or mammalian cells, enabling studies on its functional and immunological properties.
Structurally, XAGE1C is a ~24 kDa protein containing conserved XAGE family domains. Its tumor-specific expression has been observed in lung adenocarcinoma, prostate cancer, and sarcomas, correlating with metastasis and poor prognosis. As a biomarker, XAGE1C antibodies or mRNA levels in blood/samples may aid cancer diagnosis. Therapeutically, recombinant XAGE1C is investigated for cancer vaccines or T-cell therapies, leveraging its potential to elicit cytotoxic T-lymphocyte (CTL) responses against tumor cells. Preclinical studies show immunization with XAGE1C induces antigen-specific immune reactions, though clinical efficacy remains under exploration. Challenges include optimizing immunogenicity and delivery methods. Current research focuses on elucidating its molecular interactions and validating clinical utility.
×
